Danusertib, an aurora kinase inhibitor

Expert Opinion on Investigational Drugs

Volumn 21, Issue 3, 2012, Pages 383-393

  Meulenbeld, Hielke J ^a   Mathijssen, Ron H J ^a   Verweij, Jaap ^a   De Wit, Ronald ^a   De Jonge, Maja J A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Aurora kinase; Aurora kinase inhibitor; Cancer; Danusertib; Mitosis; Review

Indexed keywords

AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; AURORA KINASE INHIBITOR; BEVACIZUMAB; DANUSERTIB; DOCETAXEL; IMATINIB; SORAFENIB;

ANEMIA; ANOREXIA; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HUMAN; HYPERTENSION; LYMPHOCYTOPENIA; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHLEBITIS; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PYRAZOLES;

EID: 84856916111     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.652303     Document Type: Review

References (57)

1. Cheung CHA, Coumar MS, Hsieh HP, Chang JY. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 2009;18:379-98
2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;369:643-9. (Pubitemid 29003936)
3. Schmidt M, Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 2007;10:162-81 (Pubitemid 47449762)
4. Kitzen JJEM, de Jonge MJA, Verweij J. Aurora kinase inhibitors. Crit Rev Oncol Hematol 2010;73:99-110
5. Giet R, Petretti C, Pringent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol 2005;15:241-50 (Pubitemid 40603893)
6. Glover DM, Leibowitz MH, McLean DA, Parry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995;81:95-105.
7. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-65 (Pubitemid 28254378)
8. Carpinelli P, Moll J. Aurora kinases and their inhibitors: more than one target and one drug. Adv Exp Med Biol 2008;610:54-73
9. Brown JR, Koretke KK, Birkeland ML, et al. Evolutionary relationships of Aurora kinases: Implications for model organism studies and the development of anti-cancer drugs. BMC Evol Biol 2004; 4:39-48
10. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4: 842-54 (Pubitemid 37411723)
11. Bisshoff JR, Plowman GD. The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 1999;9:454-9 (Pubitemid 29469430)
12. Ke YW, Dou Z, Zhang J, Yao XB. Function and regulation of Aurora/Ipl1p kinase family in cell division. Cell Res 2003;13: 69-81
13. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-36 (Pubitemid 39626216)
14. Katayama H, Ota T, Jisaki F, et al. Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 1999; 91:1160-2 (Pubitemid 29330556)
15. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 2065-71
16. Dar AA, Zaika A, Piazuelo MB, et al. Frequent overexpression of aurorakinase A in upper gastro-intestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 2008;112:1688-98 (Pubitemid 351536828)
17. Reiter R, Gais P, Jutting U, et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:5136-41 (Pubitemid 44453341)
18. Karthigeyan D, Prasad SB, Shandilya J, et al. Biology of Aurora A kinase: implications in cancer manifestation and therapy. Med Res Rev 2010; 31:757-93
19. Warner SL, Bearss DJ, Han H, von Hoff DD. Targeting Aurora-2 kinase in cancer. Mol Cancer Ther 2003; 2:589-95.
20. Li JJ, Li SA. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther 2006;111:974-84 (Pubitemid 44137383)
21. Mao JH, Wu D, Perez-Losada J, et al. Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell 2007; 11:161-73 (Pubitemid 46209850)
22. Ouchi M, Fujiuchi N, Sasai K, et al. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 2004; 279:19643-8 (Pubitemid 38623401)
23. Wang X, Zhou YX, Qiao W, et al. Overexpression of Aurora kinase A in mouse mammary epithelium induces genetic instability precedeing mammary tumour formation. Oncogene 2006;25:7148-58 (Pubitemid 44764184)
24. Vader G, Medema RH, Lens SM. The chromosomal passenger complex: guiding aurora-B through mitosis. J Cell Biol 2006;173:833-7
25. Moore AS, Blagg J, Linardopoulos S, Pearson ADJ. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 2010;24:671-8
26. Dewar H, Tanaka K, Nasmyth K, Tanaka TU. Tension between the two kinetochores suffices for their bioorientation on the mitotic spindle. Nature 2004;428:93-7 (Pubitemid 38332364)
27. Goto H, Yasui Y, Kawajiri A, et al. Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation in the cytokinetic process. J Biol Chem 2003;278:8526-30 (Pubitemid 36800605)
28. Lipp JJ, Hirota T, Poser I. Aurora B controls the association of condensin I but not condensin II with mitotic chromosomes. J Cell Sci 2007;120:1245-55 (Pubitemid 46711843)
29. Tang CJ, Lin CY, Tang TK. Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis. Dev Biol 2006;290:398-410 (Pubitemid 43163501)
30. Yang KT, Li SK, Chang CC, et al. Aurora-C kinase deficiency causes cytokinesis failure in meiosis I and production of large polyploid oocytes in mice. Mol Biol Cell 2010;21:2371-83
31. Sasai K, Katayama H, Stenoien D, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 2004;59:249-63 (Pubitemid 40012993)
32. Carpinelli P, Ceruti R, Giorgini ML, et al. PHA-739358, a potent inhibitor of aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6:3158-68.
33. Fancelli D, Moll J, Varasi M, et al. 1,4,5,6-Tetrahydropyrrolo[3,4-c] pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 2006;49:7247-51. (Pubitemid 44886012)
34. Gontarewicz A, Balabanov S, Keller G, et al. Simultaneous targeting of aurora kinases and Bcr-Abl kinase by the small molecule inhibitor danusertib is effective against imatinib-resistant BCR-ABL mutations including T3151. Blood 2008; 111:4355-64.
35. Gontarewicz A, Brummendorf TH. Danusertib (formerly PHA-739358)-A novel combined pan-aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res 2010;184:199-214
36. Clarkson B, Strife A, Wisniewski D, et al. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 2003;17:1211-62 (Pubitemid 36857334)
37. Balabanov S, Gontarewicz A, Keller G, et al. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor danusertib in BCR-ABL-positive cells in vitro. PLoS ONE 2011;6(4):e19164
38. Bongarzone I, Vigneri P, Mariani L, et al. Ret/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res 1998;4:223-8 (Pubitemid 28062900)
39. Sjoblom T, Jones S, Wood L, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-74 (Pubitemid 44571966)
40. Dionne CA, Camaratto AM, Jani JP, et al. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 1998; 4:1887-98 (Pubitemid 28369172)
41. Carlomagno F, Salvatore D, Santoro M, et al. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 1995; 207:1022-8
42. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic Mouse. Proc Natl Acad Sci USA 1995;92:3439-43
43. Beltran H, Rickman D, Park K, et al. Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets. J Clin Oncol 2011;29:abstract 4536
44. Benten D, Keller G, Quaas A, et al. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009;11:934-44
45. Steeghs N, Eskens FA, Gelderblom H, et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 2009; 27: 5094-101.
46. Cohen RB, Jones SF, Aggarwal C, et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009;15: 6694-701.
47. Steeghs N, Mathijssen RHJ, Wessels JAM, et al. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. Invest New Drugs 2011; 29:953-62
48. Rosen PJ, Tolcher AW, Lee P, et al. Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors. J Clin Oncol 2010; 28(15s): abstract 3066
49. Cortes-Franco J, Dombret H, Schafhausen P, et al. Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 2009; 114: abstract 864
50. NCT00335868. PHA-739358 in treating patients with Chronic Myelogenous Leukemia that relapsed after Imatinib Mesylate or c-ABL therapy. Available from: www.ClinicalTrials.gov
51. Paquette RL, Shah NP, Sawyers CL, et al. PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I Mutations of BCR-ABL. Blood 2007; 110: abstract 1030.
52. Gallerani E, Delord J, Schoffski P, et al. Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC). J Clin Oncol 2010; 28(15s): abstract 5014.
53. Laffranchi B, De Jonge MJ, Bajetta E, et al. Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC). J Clin Oncol 2010;28:abstract e13558.
54. Bleuse JP, Meulenbeld HJ, Vinci EM, et al. Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2011;29: abstract 4628.
55. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16
56. Cheung CH, Coumar MS, Chang JY, Hsieh HP. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin Ther Patents 2011; 21:857-84
57. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011;8:244-50.